<!DOCTYPE html>
<html>
<head>
  <title>Today in Biology Part 2 (Blog Post 5) — BioCast</title>
  <link rel="stylesheet" type="text/css" href="biocastmobile.css">
  <link rel="shortcut icon" type="image/png" href="Images/BioCastDNAWhite.png">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
  <script src="index.js"></script>
  <style>
    html {
      font-family: Lato-Bold;
    }
  </style>
</head>
<body>
  <header class="header">
    <div class="topnav">
        <a href="index.html" class="homebutton"><img src="Images/BioCastDNACream.png" alt=""></a>
        <div id="myLinks">
          <a href="aboutus.html">About Us</a>
          <a href="blog.html">Blog</a>
          <a href="listenhere.html">Listen Here</a>
          <a href="contactus.html">Contact Us</a>
        </div>
        <!-- "Hamburger menu" / "Bar icon" to toggle the navigation links -->
        <a href="javascript:void(0);" class="icon" onclick="myFunction()">
          <i class="fa fa-bars fa-5x"></i>
        </a>
      </div>
  </header>
  <div class="container blog">
    <div class="blog-post">
      <h1>Today in Biology Part 2 - Zepbound Unveiled: An Innovative Solution to America's Obesity Epidemic</h1>
      <div class="center-image">
        <img src="../Images/BioCastDNACream.png" alt="Science Blog Post Image">
      </div>
      <p class="published-date">Published on December 19, 2023</p>
      <br>
      <p>Obesity is and has long been a pervasive issue in the United States, presenting a substantial challenge to public health. According to the Centers for Disease Control and Prevention (CDC), <a href="https://www.cdc.gov/nchs/products/databriefs/db360.htm#:~:text=The%20age%2Dadjusted%20prevalence%20of%20obesity%20among%20U.S.%20adults%20was,adults%20aged%2060%20and%20over." class="links" target="_blank" rel="noopener noreferrer">the prevalence of obesity in adults was 42.4% in 2017-2018</a>. This alarming figure reflects a steady increase over the years, highlighting the urgency of addressing this epidemic. The impact extends beyond adults; as childhood obesity rates have also risen, with approximately 19.3% of children and adolescents aged 2-19 classified as obese. Obesity contributes significantly to the burden of chronic diseases such as <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879283/" class="links" target="_blank" rel="noopener noreferrer">heart disease, diabetes, and certain cancers</a>. It not only diminishes individuals' quality of life but also strains the healthcare system, with obesity-related medical costs estimated to be billions of dollars annually. Tackling obesity necessitates a comprehensive and collaborative approach encompassing public health initiatives, lifestyle modifications, and policy interventions to foster a healthier nation. But what if through medication, we could aid those struggling with obesity towards these resources and methods?</p>
      <br>
      <p>Well, look no further: as of November 8, 2023, <a href="https://www.medicalnewstoday.com/articles/zepbound-explained-glp-1-weight-loss-drug-fda-approval#:~:text=The%20FDA%20recently%20approved%20a,to%20treat%20type%202%20diabetes." class="links" target="_blank" rel="noopener noreferrer">the drug Zepbound is officially FDA-approved</a>. This medication, with the generic name “tirzepatide,” has been approved for the treatment of chronic obesity, with <a href="https://news.weill.cornell.edu/news/2023/12/tirzepatide-enhances-weight-loss-with-sustained-treatment-but-discontinuation-leads-to#:~:text=Besides%20controlling%20blood%20sugar%2C%20the,body%20weight%20over%2072%20weeks." class="links" target="_blank" rel="noopener noreferrer">clinical trials showing that patients are able to lose up to 20 percent of their weight</a> in just a matter of months. But tirzepatide isn’t a new medicine, not at all: in the past, this same medicine has been sold under the brand name “<a href="https://www.mounjaro.com/" class="links" target="_blank" rel="noopener noreferrer">Mounjaro</a>,” among others, as a treatment for Type 2 diabetes. So what’s the difference, if any, between these medications? Does it even matter? As it turns out, Mounjaro and Zepbound are brand names sold by the same company, and <a href="https://ro.co/weight-loss/zepbound-vs-mounjaro/#:~:text=Zepbound%20will%20be%20available%20in,12.5%20mg%2C%20and%2015%20mg." class="links" target="_blank" rel="noopener noreferrer">the doses/concentrations of tirzepatide are the same as well</a>. As such, it appears that the differentiation is for marketing purposes, to sell two “different” (although identical) drugs for two different ailments. So how does tirzepatide even treat Type 2 diabetes and obesity? Let’s take a look.</p>
      <br>
      <p>Tirzepatide is a novel drug that belongs to the class of medicines known as <a href="https://medlineplus.gov/druginfo/meds/a622044.html#:~:text=Tirzepatide%20is%20in%20a%20class,GLP%2D1)%20receptor%20agonists." class="links" target="_blank" rel="noopener noreferrer">dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists</a>. Developed initially for the treatment of Type 2 diabetes, tirzepatide exerts its therapeutic effects through a multifaceted mechanism. After being administered (typically via injection), it stimulates the GIP receptors, which are primarily located in the gastrointestinal tract. This activation promotes the release of insulin from beta cells (usually in the pancreas) in a glucose-dependent manner. This means that tirzepatide enhances insulin secretion only when blood glucose levels are elevated, reducing the risk of hypoglycemia (low blood sugar). Then, the drug acts on GLP-1 receptors, increasing insulin secretion and suppressing glucagon release from the pancreas. These actions collectively lead to improved blood glucose control by enhancing glucose uptake in peripheral tissues and reducing glucose production by the liver. A lot of details, I know. Here’s a figure that serves as a recap:</p>
      <div class="figures">
          <img src="../Images/Post5Fig.jpg" alt="Figure 1, depicting the ways in which GLP affects the body">
      </div>
      <br>
      <p>Most recently, <a href="https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-achieved-157-weight-loss-adults-obesity-or" class="links" target="_blank" rel="noopener noreferrer">tirzepatide has been shown to induce weight loss</a>, a valuable benefit for individuals with type 2 diabetes, which is often associated with obesity. This weight loss effect is attributed to its impact on appetite regulation and modulation of energy balance. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419463/" class="links" target="_blank" rel="noopener noreferrer">Activation of the GLP-1 pathway by tirzepatide results in increased feelings of satiety and reduced food intake</a>. Moreover, this drug promotes weight loss by inhibiting glucagon release, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513137/" class="links" target="_blank" rel="noopener noreferrer">which decreases hepatic glucose production and encourages the utilization of stored fat for energy</a>. The combined actions on glucose metabolism and appetite regulation position tirzepatide as a potent therapeutic tool for individuals with type 2 diabetes, especially those grappling with obesity. By addressing both aspects concurrently, tirzepatide offers a holistic approach to diabetes management that extends beyond glycemic control to include weight loss, making it a promising solution in the battle against obesity in the context of metabolic disorders.</p>
      <br>
      <p>As medicine advances, innovative approaches to tackling obesity are emerging, providing new hope in the battle against this complex and widespread health issue. Therapies like tirzepatide exemplify the evolving landscape of obesity management, addressing metabolic dysregulation while also targeting appetite and energy balance. By leveraging a deeper understanding of the intricate hormonal interplay that contributes to weight gain, these advancements signal a shift from conventional, less effective interventions. As research progresses, such breakthroughs hold the promise of transforming obesity treatment, offering individuals a more nuanced and personalized approach to achieving and maintaining a healthy weight. We hope you enjoyed reading, and as always, stay curious.</p>
      <br>
      <div class="sign-off">
        <p>Till next time,</p>
        <p>Parth and Chinmay</p>
      </div>
      <br>
      <p>P.S.</p>
      <br>
      <p>Did you enjoy reading about the latest biology research and want to know more? Check out DailyDose, the easiest way to stay informed and educated about the ever changing health science world! Through their weekly newsletter that summarizes recent scientific literature, DailyDose works to help inform others about their health to make informed, positive health decisions. Go to <a href="http://joindailydose.com" class="links" target="_blank" rel="noopener noreferrer">joindailydose.com</a> to check out their newsletter that went out this week and sign up for free!</p>
    </div>
  </div>
  <div class="footer">
    <p>BioCast — Singh & Shirolkar 2023</p>
  </div>
</body>
</html>